The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics

T Kogai, GA Brent - Pharmacology & therapeutics, 2012 - Elsevier
Expression of the sodium iodide symporter (NIS) is required for efficient iodide uptake in
thyroid and lactating breast. Since most differentiated thyroid cancer expresses NIS, β …

Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy

J Liu, Y Liu, Y Lin, J Liang - Endocrinology and Metabolism, 2019 - synapse.koreamed.org
The retained functionality of the sodium iodide symporter (NIS) expressed in differentiated
thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine …

Enhancement of sodium/iodide symporter expression in thyroid and breast cancer

T Kogai, K Taki, GA Brent - Endocrine-Related Cancer, 2006 - erc.bioscientifica.com
The sodium/iodide symporter (NIS) mediates iodide uptake in the thyroid gland and lactating
breast. NIS mRNA and protein expression are detected in most thyroid cancer specimens …

A perspective view of sodium iodide symporter research and its clinical implications

G Riesco-Eizaguirre… - European Journal of …, 2006 - academic.oup.com
The sodium iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates
active iodide transport into the thyroid gland and into several extrathyroidal tissues, in …

The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues

G Riesco-Eizaguirre, P Santisteban… - Endocrine-Related …, 2021 - erc.bioscientifica.com
The sodium iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates
active iodide transport into the thyroid gland and into several extrathyroidal tissues. NIS …

The biology of the sodium iodide symporter and its potential for targeted gene delivery

M Hingorani, C Spitzweg, G Vassaux… - Current cancer drug …, 2010 - ingentaconnect.com
The sodium iodide symporter (NIS) is responsible for thyroidal, salivary, gastric, intestinal
and mammary iodide uptake. It was first cloned from the rat in 1996 and shortly thereafter …

Redifferentiation of radioiodine refractory differentiated thyroid cancer for reapplication of I-131 therapy

CM Hong, BC Ahn - Frontiers in endocrinology, 2017 - frontiersin.org
Although most differentiated thyroid cancers show excellent prognosis, treating radioiodine
refractory differentiated thyroid cancer (RR-DTC) is challenging. Various therapies, including …

[HTML][HTML] Quercetin and thyroid

C Giuliani, G Di Dalmazi, I Bucci, G Napolitano - Antioxidants, 2024 - mdpi.com
Quercetin is the most abundant flavonoid present in fruits and vegetables. For its
antiproliferative, antiviral, anti-inflammatory and antioxidants activities, it is an active …

NF-κB p65 Subunit Mediates Lipopolysaccharide-Induced Na+/I Symporter Gene Expression by Involving Functional Interaction with the Paired Domain …

JP Nicola, M Nazar, ID Mascanfroni… - Molecular …, 2010 - academic.oup.com
The Gram-negative bacterial endotoxin lipopolysaccharide (LPS) elicits a variety of
biological responses. Na+/I− symporter (NIS)-mediated iodide uptake is the main rate …

Systemic treatments for radioiodine-refractory thyroid cancers

P Chen, Y Yao, H Tan, J Li - Frontiers in Endocrinology, 2024 - frontiersin.org
Differentiated thyroid cancers (DTCs) constitute the primary histological subtype within
thyroid cancer. Due to DTCs' distinctive radioiodine (RAI) uptake mechanism, standard …